China accepts NDA for BeiGene's zanubrutinib for MCL

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) said China’s National Medical Products Administration accepted an NDA for

Read the full 141 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE